These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4767492)

  • 21. The prolonged release of caramiphen hydrochloride and atropine sulfate from compressed tablets containing carbopol 934.
    Baun DC; Walker GC
    Pharm Acta Helv; 1971 Feb; 46(2):94-113. PubMed ID: 5142666
    [No Abstract]   [Full Text] [Related]  

  • 22. Extrudable core system: development of a single-layer osmotic controlled-release tablet.
    Waterman KC; MacDonald BC; Roy MC
    J Control Release; 2009 Mar; 134(3):201-6. PubMed ID: 19100796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model for the drug release from a polymer matrix tablet--effects of swelling and dissolution.
    Borgquist P; Körner A; Piculell L; Larsson A; Axelsson A
    J Control Release; 2006 Jul; 113(3):216-25. PubMed ID: 16797098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets.
    Ozeki Y; Ando M; Watanabe Y; Danjo K
    J Control Release; 2004 Feb; 95(1):51-60. PubMed ID: 15013231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended release of a large amount of highly water-soluble diltiazem hydrochloride by utilizing counter polymer in polyethylene oxides (PEO)/polyethylene glycol (PEG) matrix tablets.
    Kojima H; Yoshihara K; Sawada T; Kondo H; Sako K
    Eur J Pharm Biopharm; 2008 Oct; 70(2):556-62. PubMed ID: 18606223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hydrophilic natural gums in formulation of oral-controlled release matrix tablets of propranolol hydrochloride.
    Rajesh KS; Venkataraju MP; Gowda DV
    Pak J Pharm Sci; 2009 Apr; 22(2):211-9. PubMed ID: 19339235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of powder blend and tablet structure on drug release mechanisms of hydrophobic starch acetate matrix tablets.
    van Veen B; Pajander J; Zuurman K; Lappalainen R; Poso A; Frijlink HW; Ketolainen J
    Eur J Pharm Biopharm; 2005 Oct; 61(3):149-57. PubMed ID: 16005196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).
    Okimoto K; Tokunaga Y; Ibuki R; Irie T; Uekama K; Rajewski RA; Stella VJ
    Int J Pharm; 2004 Nov; 286(1-2):81-8. PubMed ID: 15501004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation of a extended release tablet containing dexibuprofen.
    Yi HG; Chi MH; Kim YI; Woo JS; Park ES
    Arch Pharm Res; 2008 Dec; 31(12):1637-43. PubMed ID: 19099235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study on maize proteins as a potential new tablet excipient.
    Georget DM; Barker SA; Belton PS
    Eur J Pharm Biopharm; 2008 Jun; 69(2):718-26. PubMed ID: 18294824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs. Influences of the surface properties of liposomes and the crosslinked fibrin network.
    Chung TW; Yang MC; Tsai WJ
    Int J Pharm; 2006 Mar; 311(1-2):122-9. PubMed ID: 16446064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
    Al-Kassas RS; Al-Gohary OM; Al-Faadhel MM
    Int J Pharm; 2007 Aug; 341(1-2):230-7. PubMed ID: 17507189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer.
    Abdelbary GA; Tadros MI
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1019-28. PubMed ID: 18295465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theophylline loaded gastroretentive floating tablets based on hydrophilic polymers: preparation and in vitro evaluation.
    Khan F; Ibn Razzak SM; Khan ZR; Azad MA; Chowdhury JA; Reza S
    Pak J Pharm Sci; 2009 Apr; 22(2):155-61. PubMed ID: 19339225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Floating hot-melt extruded tablets for gastroretentive controlled drug release system.
    Fukuda M; Peppas NA; McGinity JW
    J Control Release; 2006 Oct; 115(2):121-9. PubMed ID: 16959356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The preparation of nitroglyerin tablets with protracted action].
    Krówczynski L; Stozek T; Rogacka K
    Pharmazie; 1978 Jun; 33(6):354-6. PubMed ID: 98773
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of pharmaceutical availability of salicylic acid from tablets containing amphoteric surfactants.
    Bialik W; Jaworski E
    Pharmazie; 1990 May; 45(5):376-7. PubMed ID: 2395904
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advances in the production and control of tablets. XVI. Various types of oral preparations with delayed action].
    Chalabala M; Vitková M
    Cesk Farm; 1976 Mar; 25(2):79-81. PubMed ID: 1277318
    [No Abstract]   [Full Text] [Related]  

  • 39. [Manufacturing delayed action tablet using sugar cane wax].
    Orbán E; Isaura LV
    Acta Pharm Hung; 1973 Jan; 43(1):9-13. PubMed ID: 4687825
    [No Abstract]   [Full Text] [Related]  

  • 40. Urinary excretion of potassium from sustained-release tablets.
    Otto U; Rooth G
    Acta Pharm Suec; 1973 Sep; 10(4):337-42. PubMed ID: 4759359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.